

**Amendments to the Claims:**

This listing of claims will replace all previous versions and listings of claims in the application:

1. (currently amended) A method for inhibiting aberrant neuron sprouting in epilepsy *in vivo*, comprising contacting a full-length human trkC receptor of SEQ ID NO: 6 expressed in epileptic neuronal cells with an antagonistic antibody capable of specifically binding to a full-length trkC receptor sequence comprising amino acid residues 32 to 839 of SEQ ID NO: 6, wherein said antibody binding inhibits the activity of said trkC receptor.

2.-3. (canceled)

4. (original) The method of claim 1 wherein said antibody is a monoclonal antibody.

5. (original) The method of claim 1 wherein said antibody is an antibody fragment selected from the group consisting of Fab, Fa(ab'), F(ab')<sub>2</sub>, and Fv.

6. (original) The method of claim 1 wherein said antibody is selected from monospecific antibodies, bispecific antibodies and heteroconjugate antibodies.

7. (original) The method of claim 1 wherein said antibody is a human antibody or a humanized antibody.

8-22. (canceled)

23. (currently amended) A method for the treatment of ~~a pathological~~ an epileptic condition ~~associated with elevated NT-3 production~~ comprising aberrant neuron sprouting in a subject suffering from said epileptic condition, comprising treating said subject with a therapeutically effective amount of an antibody capable of specifically binding to a full-length trkC receptor sequence in an epileptic neuronal cell comprising amino acid residues 32 to 839 of SEQ ID NO: 6, wherein said antibody binding inhibits the activity of said full-length trkC receptor.

24.-25. (canceled)